Totally three articles focusing on "gene therapy of Parkinson\'s disease, the effect of levodopa on toxicity of dopaminergic neurons in substantia nigra and striatum, and the effect of rifampicin on reducing Parkinson\'s disease-induced dopaminergic neuronal apoptosis" are published in three issues. We hope that our readers find these papers useful to their research.

**Abstract**

Gene therapy for Parkinson\'s disease is being explored as an effective strategy to restore and protect the function of neuronal cells in the substantia nigra. Regulation of gene expression is necessary for gene therapy to avoid adverse effects due to excessive synthesis of transgene products. In the present study, to construct a recombinant AAV vector carrying a dopamine synthase gene. The tyrosine hydroxylase gene was inserted using a loxP fragment that could be regulated by Cre recombinase. The recombinant AAV vector carrying the CreER^T2^ gene was co-transduced with HEK293 cells and the corpus striatum in a rat model of Parkinson\'s disease, with inducing agent tamoxifen to regulate gene expression. We found that the application of AAV vector-encoded tyrosine hydroxylase gene under the gene regulation system of Cre-ER^T2^, after tamoxifen treatment, can effectively control the generation of genetically modified products to reduce the production of excessive dopamine *in vivo* and *in vitro*. Therefore, this method can increase the safety of gene therapy.
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**Abstract**

Rifampicin inhibits the formation of α-synuclein multimer and protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyritine-induced PC12 cell apoptosis. In this study, rifampicin was intragastrically administered 3 days prior to rotenone induction and 7 days after rotenone induction for 3 successive weeks in total. Rifampicin significantly attenuated neuropathological and behavioral motor deficits induced by rotenone. Moreover, rifampicin enhanced tyrosine hydroxylase expression, but inhibited α-synuclein expression. The effect of rifampicin pre-treatment was superior to rifampicin post-treatment.
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**Abstract**

Rat model of Parkinson\'s disease was established by injecting 6-hydroxydopamine into the right medial forebrain bundle. The ratio (*R* value) of specific radioactive uptake in the corpora striatum (left/right) used for evaluating the number and function of dopamine transporters was significantly increased. Autoradiographic results of dopamine transporter showed that the radio-ligand accumulation in the right corpus striatum was sparse compared with that in the left corpus striatum. The specific radioactivity uptake was obviously reduced in the right (injured) hemisphere of rats with dyskinesia induced by intraperitoneal injection of levodopa and the *R* value was significantly increased in rats receiving levodopa compared with rats receiving only normal saline. The *R* value was significantly decreased in rats without abnormal involuntary movement compared with rats with abnormal involuntary movement. The specific radioactive uptake on the injured side was increased compared with the healthy side. The radio-ligand accumulation was observed in the right corpus striatum, and differences in radio-ligand accumulation between the two sides were reduced. Following levodopa treatment, the number and function of dopamine transporter in some Parkinson\'s disease rats were reduced. Levodopa was shown to be toxic to dopaminergic neurons and induced dyskinesia.
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